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Behavioral/Cognitive
MDMA Increases Cooperation and Recruitment of Social
Brain Areas When Playing Trustworthy Players in an
Iterated Prisoner’s Dilemma
X Anthony S. Gabay,1 Matthew J. Kempton,1,2 James Gilleen,2,3* and Mitul A. Mehta1*
1Department of Neuroimaging, 2Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5
8AF, United Kingdom, and 3Department of Psychology, University of Roehampton, London SW15 5PJ, United Kingdom
Social decision-making is fundamental for successful functioning and can be affected in psychiatric illness and by serotoninergic mod-
ulation. The Prisoner’s Dilemma is the archetypal paradigm to model cooperation and trust. However, the effect of serotonergic enhance-
ment is poorly characterized, and its influence on the effect of variations in opponent behavior unknown. To address this, we conducted
a study investigating how the serotonergic enhancer 3,4-methylenedioxy-methamphetamine (MDMA) modulates behavior and its neural
correlates during an iterated Prisoner’s Dilemma with both trustworthy and untrustworthy opponents. We administered 100 mg MDMA
or placebo to 20 male participants in a double-blind, placebo-controlled, crossover study. While being scanned, participants played
repeated rounds with opponents who differed in levels of cooperation. On each round, participants chose to compete or cooperate and
were asked to rate their trust in the other player. Cooperation with trustworthy, but not untrustworthy, opponents was enhanced
following MDMA but not placebo (respectively: odds ratio  2.01; 95% CI, 1.42–2.84, p  0.001; odds ratio  1.37; 95% CI, 0.78 –2.30, not
significant). Specifically, MDMA enhanced recovery from, but not the impact of, breaches in cooperation. During trial outcome, MDMA
increased activation of four clusters incorporating precentral and supramarginal gyri, superior temporal cortex, central operculum/
posterior insula, and supplementary motor area. There was a treatment  opponent interaction in right anterior insula and dorsal
caudate. Trust ratings did not change across treatment sessions. MDMA increased cooperative behavior when playing trustworthy
opponents. Underlying this was a change in brain activity of regions linked to social cognition. Our findings highlight the context-specific
nature of MDMA’s effect on social decision-making.
Key words: fMRI; MDMA; Prisoner’s Dilemma; psychopharmacology; social cognition; social decision-making
Introduction
Social cognitive deficits are recognized as a fundamental diffi-
culty in a range of psychiatric conditions, and current medica-
tions do not effectively treat these deficits (Gabay et al., 2015;
Kupferberg et al., 2016). These disruptions encompass social
decision-making tasks, designed to investigate behavior in stra-
tegic social situations, where outcomes depend not only on one’s
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Significance Statement
We provide a detailed analysis of the effect of 3,4-methylenedioxy-methamphetamine (MDMA) on cooperative behavior during
interpersonal interactions, as well as the neural correlates underlying these effects. We find that, following administration of
MDMA, participants behave more cooperatively, but only when interacting with trustworthy partners. While breaches of trust-
worthy behavior have a similar impact following administration of MDMA compared with placebo, MDMA facilitates a greater
recovery from these breaches of trust. Underlying this altered behavior are changes in brain activity during the viewing of
opponents’ behavior in regions whose involvement in social processing is well established. This work provides new insights into
the impact of MDMA on social interactions, emphasizing the important role of the behavior of others toward us.
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own behavior, but also on that of an interacting partner (Mc-
Clure et al., 2007; Radke et al., 2013).
The Prisoner’s Dilemma (PD) is a prototypical social decision-
making game where two players simultaneously choose to cooperate
with or compete against each other. Points are allocated based on the
combination of their responses. Mutual cooperation is the best com-
bined outcome; however, by cooperating, one risks betrayal. Betray-
ing a cooperator attracts the highest points available and results in
the lowest points for the player who is betrayed.
Emerging evidence suggests that manipulation of the sero-
toninergic system affects social decision-making (Wood et al.,
2006; Crockett et al., 2010). However, specific assessment of se-
rotonergic manipulation on trust and cooperation in the PD is
lacking, with the exception of Wood et al. (2006) who reported
that acute tryptophan depletion reduced cooperative responses
compared with a placebo control condition.
Neuroimaging can address whether pharmacological manip-
ulation influences specific cognitive components, such as receiv-
ing feedback or making decisions. PD studies have implicated
brain regions during feedback, which have been shown to be
involved in social processing, including the superior temporal
sulcus, temporal-parietal junction, and posterior cingulate gyrus
(Rilling et al., 2004; Suzuki et al., 2011). Oxytocin administration
altered neural activity when receiving feedback about other play-
ers’ decisions, with the insula, amygdala, and caudate nucleus
being implicated (Rilling et al., 2012; Chen et al., 2017).
The characteristics of PD opponents can have a significant
impact on PD behavior, exemplified by Sorgi and Van ‘t Wout
(2016) who showed that depression severity was correlated with
cooperation when playing trustworthy opponents, but not un-
trustworthy opponents. This makes a case for testing the influ-
ence of pharmacological manipulations on different opponent
types, in particular to test whether effects are limited to trustwor-
thy or untrustworthy opponents.
We performed a functional neuroimaging study investigating
the effect of 3,4-methylenedioxy-methamphetamine (MDMA)
on PD behavior. MDMA was chosen because it produces pro-
found social and emotional effects and is commonly described in
terms of its effects on interpersonal interactions. The neurophar-
macological mechanisms of MDMA are mixed. It elicits the re-
lease of dopamine (DA), noradrenaline (NA), and serotonin,
with the latter believed to be primarily responsible for its social
and euphoric effects (Rudnick and Wall, 1992; Kuypers et al.,
2014).
Participants played repeated rounds of a newly developed ver-
sion of the PD with three types of opponents: trustworthy (mostly
cooperative), untrustworthy (mostly uncooperative), and a non-
social control. Thus, we were able to test for differential effects of
MDMA on different types of opponent. Additionally, on each
round, participants were asked to rate their trust in the other
player. The task was performed during functional neuroimaging,
allowing us to examine the neural correlates of MDMA-induced
changes in behavior.
We also tested other components of social cognition by in-
cluding an emotion recognition task and empathy task outside of
the scanner. Kuypers et al. (2017) show that MDMA increased
affective, but not cognitive, empathy. Other research found that
MDMA reduces recognition of fearful, angry, and sad facial ex-
pressions (Hysek et al., 2014; Kirkpatrick et al., 2014; Schmid et
al., 2014). We sought to reproduce these effects and conducted an
additional exploratory analysis to determine their relationship to
changes in PD behavior under the influence of MDMA.
For the PD, we hypothesized that MDMA would increase co-
operation with both types of “human” opponent and increase
trust ratings for these opponents. We expected that none of these
changes would be seen when playing the nonsocial control oppo-
nent. We hypothesized that previously implicated social cogni-
tion regions (Wood et al., 2006; Rilling et al., 2004, 2012),
including the superior temporal cortex, temporal parietal junc-
tion, and the posterior cingulate cortex, would show increased
activity when playing the game during the MDMA session com-
pared with the placebo session.
Materials and Methods
Participants. Twenty-one male participants were recruited from the com-
munity. We collected written informed consent, and participants were
financially compensated for their time. The study received ethical ap-
proval from King’s College London’s Psychiatry, Nursing and Midwifery
Research Ethics Committee (PNM/14/15-32). All participants had at
least one previous experience with MDMA.
One participant withdrew from the study after his first visit. This was
unrelated to his participation, and unblinding revealed that he received
placebo on that visit. Therefore, 20 participants completed the study
(mean  SD age, 24.8  3.7 years; range  21–37 years).
Participants had no history of psychiatric illness or other neurological
disorders, and were asked to refrain from MDMA use for 3 months, and
caffeine and alcohol for 24 h, before each study visit. All participants
passed a urine-based drugs-of-abuse test before dosing on each study
visit. This tested for 10 classes of substance: cocaine, opioids, MDMA,
THC, amphetamines, barbiturates, tricyclic antidepressants, metham-
phetamine, methadone, and benzodiazepines. We did not formally col-
lect data on frequency of previous drug use, but all participants were
assessed for substance dependency at screening. Participants were re-
quired to not be taking other medications throughout their involvement
in the study; and if this was not possible, they were excluded from taking
part.
Subjective effects. At the end of each experimental session, participants
were asked to complete the Altered States of Consciousness (ASC) ques-
tionnaire. This is an 11-dimension questionnaire and is the gold standard
when investigating compounds with psychedelic-like properties (Stude-
rus et al., 2011).
The PD. A new, computerized, iterated version of the PD was de-
veloped by Gilleen and Satkunanathan (2015) which allows measure-
ment of both social decision-making and changes in trust during
social interaction. This PD paradigm has shown sensitivity to distin-
guishing paranoia profiles in high and low schizotypes (Gilleen and
Satkunanathan, 2015). Using this paradigm, participants were led to
believe that they would log onto a shared network, established in
collaboration with two other London-based universities. They were
told this network had been designed to allow participants from each
site to interact in different tasks. In reality, opponent responses were
preprogrammed by the research team.
Participants played an iterated PD with three different types of oppo-
nent (for the payoff matrix used, see Fig. 1B). They were told they would
play between 8 and 15 rounds with each player but in fact played 15
rounds.
On each round (Fig. 1A), participants were asked to decide whether to
compete or cooperate with the other player, then received feedback as
to the other player’s choice and the distribution of points, then asked
to rate their trust in the other player from 1 to 7. The three types of
opponent were as follows: (1) trustworthy, cooperated 12 of 15
rounds; (2) untrustworthy, cooperated 3 of 15 rounds; and (3) game
server, with this opponent, participants were explicitly told they
would be playing with a random response generator. The design of the
opponent behavior was fixed across participants to allow us to assess
Correspondence should be addressed to Dr. Anthony S. Gabay, Centre for Neuroimaging Sciences, Institute of Psychiatry,
Psychology & Neuroscience (089), De Crespigny Park, London SE5 8AF, UK. E-mail: anthony.a.gabay@kcl.ac.uk.
https://doi.org/10.1523/JNEUROSCI.1276-18.2018
Copyright © 2019 the authors 0270-6474/19/390308-14$15.00/0
308 • J. Neurosci., January 9, 2019 • 39(2):307–320 Gabay et al. • MDMA Prisoner’s Dilemma
the role of the opponent behavior in terms of trustworthiness. A
different design, such as a tit-for-tat strategy, would also allow us to
address the impact of MDMA on the PD as a function of opponent
behavior but would be less controlled and require larger group sizes.
Furthermore, the use of such a response algorithm could result in
convergence of outcomes toward complete cooperation or competi-
tion, thus making it impossible to address our question on the effect
of trustworthiness. A potential advantage of this alternative approach
is that trustworthiness may be included as a continuous moderator,
but this was beyond the scope of this study.
They played each type of opponent type twice (but were told they
had connected to a different “player” for each opponent). Partici-
pants were given no prior information about the opponent. Because
of the length of the task, it was split into two runs, lasting 9 min 15 s
each. In the first run of each session, the order of opponents was as
follows: trustworthy-game server-untrustworthy. In the second run
of each session, the order of opponents was as follows: untrustworthy-
game server-trustworthy.
All participants completed a practice version of the task at the
screening visit. Participants were debriefed as to the deception at the
end of the study, and belief in the deception was confirmed during
this debrief.
Emotion recognition and empathy tasks. The Affective Bias task was
taken from the EMOTICOM cognitive test battery (Bland et al., 2016)
and administered 195 min after dose. In this task, participants see a face
appear on the screen for 500 ms and are asked to indicate which emo-
tion the face was expressing from a choice of happy, sad, fear, or anger.
For each emotion, there are nine levels of intensity. Control conditions of
faces of different ages were also presented. There were 20 presentations of
each emotion and 20 control faces.
The Multifaceted Empathy Test (MET) (Dziobek et al., 2008) is a task
able to assess cognitive and affective empathy separately, and has been
used in MDMA studies previously (Hysek et al., 2014; Kuypers et al.,
2014; Schmid et al., 2014). The MET was administered 180 min after
dose. The MET uses 40 images of people in ecologically valid, naturalistic
situations. In 40 trials, participants are asked to identify the emotion the
person may be feeling of a choice of 4 (cognitive empathy); and in 40 other
trials, they are asked to rate how much they empathize with the person
depicted on a scale of 1 to 9 (affective empathy). Cognitive empathy is given
a score of 40, and affective empathy is the average rating of 9.
Experimental design and statistical analysis. This study followed a
double-blind, placebo-controlled, crossover, counterbalanced design.
Participants attended two experimental study days at least 1 week apart
(mean 9.3, SD 5.7, range 7–31 d). This study additionally collected
resting-state fMRI, arterial spin labeling, and data on the Ultimatum
Game. These are reported previously. MDMA (100 mg) or placebo was
administered at 10:15. Blood samples measuring plasma MDMA levels
were taken at two time points: 45 min after dose (mean: 91.7 g/L, SD:
60.2) and 165 min after dose (mean: 188.2 g/L, SD: 32.8). Samples to
measure plasma oxytocin levels were also taken at this time. The PD was
completed in two separate runs during functional neuroimaging, begin-
ning 95 min after dose. The timing for the MRI session was chosen
because the Tmax of MDMA ranges between 1.5 and 3 h (Kolbrich et al.,
2008), and subjective effects peak and remain stable between 1 and 3 h
(Harris et al., 2002), meaning functional acquisitions would fall within
these time points. The Affective Bias and MET (see below) were com-
pleted 3 h after dose.
Two outcome measures were collected from the PD. The first were
categorical (compete or cooperate) decisions, and the second were trust
ratings of 7. The categorical data were analyzed using repeated-measures
logistic regression, implemented with generalized estimating equations
using SPSS Statistics for Windows 2012 (IBM). The odds ratio (OR)
represents the change in probability of an event (a cooperate decision)
occurring with a change in condition (trustworthiness, treatment).
In all models, participant ID was defined as the subject variable so that
each participant’s responses were nested together. First, a model testing
for a main effect of run and the run  treatment interaction was per-
formed. We also assessed the treatment order and effect of time in two
separate models. The first looked at treatment order and its interaction
with treatment. The second looked at the main effect of visit number and
its interaction with time. Next, a model testing the main effects of treat-
ment and opponent (trustworthy, untrustworthy, game server), and
their interaction, was analyzed.
Trust ratings were collected on each round, producing a total of 15
ratings for each opponent. To account for uncertainty at the beginning of
each game, the mean of the last eight rounds was calculated as the rating
Figure 1. The Prisoner’s Dilemma. A, Paradigm with timings. B, Payoff matrix.
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for each opponent. For each type of opponent, this was averaged across
runs. A repeated-measures ANOVA was performed to assess differences
in trust rating across opponent type and experimental session, with post
hoc pairwise comparisons performed where appropriate.
The outcome measure for affective bias task was the percentage correct
for each emotion (fear, anger, happy, sad) and the control condition.
Additionally, one can calculate an “affective bias,” defined by Bland et al.
(2016) as the difference between happy and sad emotion accuracy. These
outcome measures were compared across experimental sessions using
repeated-measures ANOVA, followed by post hoc pairwise comparisons
where appropriate.
The MET gives the following outcome measures: a positive valence
affective empathy measure, negative valence affective empathy measure,
and three measures for cognitive empathy (total, positive affect, negative
affect). Following advice from the group who created the task, there is no
pooled measure for total affective empathy (I. Dziobek, personal com-
munication). Each of these was assessed with paired-samples t tests to
assess differences across experimental sessions.
MRI data acquisition and analysis. Functional images were acquired
with a General Electric MR750 3.0 tesla (T) MR scanner using a 32-
channel head coil. A T2*-weighted echo-planar imaging sequence was
used, with the following parameters: TR 2000 ms, TE 30 ms, flip angle
75°, slice thickness 3 mm, FOV 247 mm, number of slices 41. The PD had
282 time points per run. We also acquired a T1 structural MPRAGE
image with the following parameters: TR 7312 ms, TE 3.02 ms, flip angle
11°, slice thickness 3 mm, 196 sagittal slices, FOV 270 mm.
Data were preprocessed and analyzed using SPM12 (Wellcome De-
partment of Cognitive Neurology, London). Before first-level modeling,
fMRI data were reoriented, slice time-corrected, and realigned initially to
the first image and then to the mean image. These were then coregistered
to the T1 structural file. The structural data were segmented to aid spatial
normalization, and a common group-specific template was created using
DARTEL registration. The functional files were then normalized to the
MNI template using deformation flow fields and structural template
created through DARTEL. Finally, functional images were smoothed
using an 8 mm FWHM Gaussian kernel.
Both runs of the task were included in a single GLM first-level model.
A simple model was defined with each condition (trustworthy, untrust-
worthy, game server opponents) by trial phase (decision, feedback, trust
rating) combination. The decision and feedback phases were defined
with durations of 3 s, and the trust rating with 5 s duration. Seven move-
ment parameters (six standard parameters as well as volume-to-volume
movement) were included as regressors of no interest. Volumes where
the volume-to-volume movement exceeded 1 mm, as well the volume
before and after, were also modeled as regressors of no interest.
At the second level, a series of whole-brain analyses were performed.
First, we examined the main effects of the task by collapsing data across
opponent types and performing a one-sample t test for each phase (de-
cision, feedback, trust rating) of the task in the placebo condition. Three
one-way, repeated-measures ANOVAs were performed on the placebo
session data to examine differences in activation across opponents for
each of the phases.
Next, we performed a series of flexible factorial analyses incorporating
opponent type and treatment as within-subject factors, separately for
each phase of the task (decision, feedback, trust rating). All maps were
thresholded at FWE cluster-corrected p  0.05 (cluster-defining thresh-
old p  0.001).
Results
Subjective effects of MDMA
Figure 2 represents the 11 dimensions of the ASC. We found an
increase in ratings for all dimensions, except “elemental imag-
ery,” after MDMA compared with placebo.
Plasma oxytocin
Table 1 displays the plasma oxytocin levels at three time points:
15 min before dose, and 45 min and 165 min after dose. MDMA
produced a large increase in plasma levels.
Emotion recognition
Due to technical problems, we had missing data for 2 participants
in the Affective Bias task. Therefore, these analyses were based on
N  18. Summary statistics for this task can be found in Table 2.
In the Affective Bias task (Bland et al., 2016), MDMA did not
alter participants’ ability to recognize and make judgments on
faces in the nonemotional control condition, compared with pla-
cebo (mean difference between scores in the MDMA and placebo
condition  4.8, SD  12.6, t(17)  1.64, p  0.120). A 2
(treatment: placebo, MDMA)  4 (emotion: happy, sad, fear,
anger) repeated-measures ANOVA found no main effect of treat-
ment (F(1,17)  2.56, p  0.128, ́
2  0.13), but both a main
effect of emotion (F(3,51)  29.22, p  0.001, ́
2  0.63) and a
treatment  emotion interaction (F(1,17)  3.56, p  0.029,
́2  0.16).
Post hoc comparisons found that participants were more ac-
curate in identifying happy emotions compared with all others
(all Bonferroni-corrected p values 0.003); anger was identified
less accurately than all other emotions (all Bonferroni-corrected
p values 0.001); there was no difference in accuracy in identify-
ing sad compared with fearful faces. The interaction appeared to
be driven by reduced accuracy in identifying fear and anger dur-
ing the MDMA session compared with the placebo.
These results support previous evidence that MDMA reduces
negative affect recognition (Bedi et al., 2010; Hysek et al., 2014;
Kirkpatrick et al., 2014).
Empathy
Because of computing problems during one session, we had miss-
ing data for 1 participant in the MET. Therefore, these analyses
were based on N  19. Summary statistics for this task can be
found in Table 2.
Paired-samples t tests showed that there were no differences
for any comparison across treatment sessions (all p values 
0.148).
This finding does not replicate previous findings with regard
to enhanced empathic processing with MDMA administration,
recently confirmed with a pooled analysis of six studies (Kuypers
et al., 2017). The mean placebo score for positive valence, explicit
affective empathy in our study was 5.5. Interestingly, the equiva-
lent score in the pooled analysis ranged from 4.2 to 5.6. There-
fore, the possibility exists that the current sample’s high baseline
empathic responses made a discernible increase following
MDMA administration less likely.
PD behavior
When assessing the effect of completing the task across two runs
on each treatment session, no main effect of run was found, but
there was a treatment  run interaction (respectively:  2(1,19) 
0.26, p  0.614;  2  7.70, p  0.021), such that there was an
increase in the probability of a cooperative response in the second
run during the MDMA session compared with the first run
(OR  1.28, 95% CIs 1.01–1.58).
The interaction effect was driven by a small but consistent
increase in cooperation on the second run of the task during the
MDMA session, which was not seen on the placebo session. The
participant-wise mean difference from the first run to the second
run on the MDMA session was 0.32 (SD 13.27). During the pla-
cebo session, there was a mean difference of 0.63 (SD 10.30).
Putting this in context, the mean cooperation rate for the MDMA
and placebo sessions (across all opponents) was 50.0% and
42.4%, respectively.
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We did not consider this to be of practical significance; and
because the effect is restricted to only the MDMA treatment ses-
sion, all other analyses were combined data across runs.
We then assessed the main effect of visit number and its inter-
action with treatment, collapsed across opponent type. There was
neither a main effect nor interaction (p  0.453 and p  0.102,
respectively). Additionally, we tested for a main effect of treat-
ment order and its interaction with treatment. Again, there was
neither a main effect nor interaction (p  0.102 and p  0.453,
respectively).
We assessed differences in trust rating across opponent type
and experimental session. Table 3 displays these data. A 2 (treat-
ment: placebo, MDMA)  3 (Trustworthiness: trustworthy, un-
trustworthy, game server) repeated-measures ANOVA revealed a
main effect of trustworthiness (F(2,38)  25.39, p  0.001,
́2  0.57), but no main effect of treatment, nor an interaction
(respectively: F(1,19)  1.53, p  0.232, ́
2  0.07; F(2,38)  0.08,
p  0.928, ́2  0.01).
Figure 3A displays the percentage of cooperate decisions when
playing each opponent type, across treatment sessions.
There was a statistically significant main effect of treatment,
trustworthiness, and its interaction (all p values 0.005). MDMA
increased the probability of a cooperative decision when playing
a trustworthy player ( 2(1,19)  15.33, OR  2.01; 95% CI, 1.42–
2.84, p  0.001), but not when playing an untrustworthy player
(OR  1.37; 95% CI, 0.78 –2.30) or the game server (OR  1.03;
95% CI, 0.71–1.48). To explore this effect further, the mean pro-
portion of cooperative decisions were plotted on a round 
round basis for each opponent type (Fig. 3).
For the untrustworthy opponent, Figure 3D shows a steady
decline in cooperation over the course of the game, regardless of
experimental session. Visual examination of Figure 3C shows a
difference across sessions for the trustworthy opponent: follow-
ing the first decision to compete by these opponents, a greater
proportion of participants continued to cooperate more in the
MDMA session than the placebo session. It seems the overall
Figure 2. Radar graph displaying scores on the 11 dimensions of the ASC questionnaire. Each line in the radar indicates 10% of the total possible score (inner point  0%; outer ring  60%).
**Bonferroni-corrected p  0.05. Experience of unity (t(19)  5.06, p  0.001); spiritual experience (t(19)  4.96, p  0.001); blissful state (t(19)  7.79, p  0.001); insightfulness (t(19)  4.96,
p  0.001); disembodiment (t(19)  4.15, p  0.001); impaired cognition (t(19)  4.02, p  0.001); anxiety (t(19)  3.81, p  0.001); complex imagery (t(19)  4.54, p  0.001); elemental
imagery (t(19)  1.53, p  0.141); audio/visual synesthesia (t(19)  4.12, p  0.001); and meaning (t(19)  5.92, p  0.001).
Table 1. Plasma oxytocin levels measured at three time pointsa
Time point Placebo session MDMA session t statistic
Bonferroni-
corrected p
15 min before dose 3.81 (4.3) 4.48 (5.1) 0.63 0.5373
45 min after dose 3.00 (3.3) 7.3 (8.7) 2.60 0.054
165 min after dose 3.09 (4.0) 20.86 (12.9) 5.66 0.001
aData are mean (SD) plasma oxytocin level (pg/ml). N  20, except 45 min after dose due to placebo session levels
of 1 participant being below the range of sensitivity at time point.





(% correct) t statistic p
Affective Bias
Nonemotion Control 85.8 (12.1) 90.6 (6.2) 1.64 0.120
Happy 90.6 (9.5) 91.4 (6.1) 0.33 0.749
Sad 71.7 (15.4) 71.7 (21.9) 0.07 0.946
Fear 79.2 (13.7) 70.8 (16.9) 2.21 0.041
Anger 60.3 (13.1) 53.1 (15.6) 2.25 0.038
MET
Cognitive Empathy
Total 73.0 (6.6) 71.4 (8.0) 1.00 0.330
Positive Valence 77.9 (6.0) 74.7 (9.3) 1.51 0.148
Negative Valence 68.1 (11.3) 68.1 (10.6) 0.01 1.00
Affective Empathy (rating out of 9)
Positive Valence 5.5 (1.1) 5.8 (1.1) 0.91 0.377
Negative Valence 4.4 (1.9) 4.5 (2.3) 0.285 0.779
aData are mean (SD). Post hoc p values are uncorrected for multiple comparisons.
Table 3. Mean (SD) trust ratings of each opponent type in each treatment sessiona
Experimental session
Opponent type Placebo MDMA
Trustworthy 4.8 (1.2) 5.0 (1.4)
Untrustworthy 2.0 (1.2) 2.2 (1.4)
Game server 2.9 (1.6) 3.2 (1.5)
aRating scale 1–7.
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Figure 3. Boxplots: A, PD cooperation rates with each type of opponent. Green dots represent placebo session. Orange dots represent MDMA session. B, The sequence of opponent responses.
Here we show the lining up of decisions across runs: to account for the jitter in opponent responses, the last trial of the first run and first trial of the final run were removed. “C,” Opponents were
congruous with their trustworthiness; “D,” opponents deviated from this. C, Proportion of cooperate decisions on each round, averaged across participants, for the trustworthy opponent. D,
Proportion of cooperate decisions on each round, averaged across participants for the untrustworthy opponent. E, Proportion of cooperate decisions on each round (Figure legend continues.)
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steady decline in cooperation differs across sessions, as visualized
in Figure 3E. This figure plots the data as scatterplots and includes
a line of best fit.
To test this formally, we performed an exploratory analysis on
the round  round data, defining a new model in the generalized
estimating equation framework. We included the round number
as a covariate and modeled the main effect of round as well as
treatment, opponent type, and their three-way interaction. We
found no main effect of treatment ( 2(1,19)  0.03, p  0.853) but
did find a main effect of opponent type ( 2(1,19)  69,72 p 
0.001), round ( 2(1,19)  44.87, p  0.001), and a three-way in-
teraction ( 2(1,19)  11.30, p  0.003). Post hoc tests revealed that,
for all three opponent types, there was a statistically significant
main effect of round such that there was a decreased probabil-
ity of a cooperate decision as the game progressed (trustworthy:
 2(1,19)  15.06, OR  0.90; 95% CI, 0.87– 0.93, p  0.001; un-
trustworthy:  2(1,19)  48.04, OR  0.84; 95% CI, 0.79 – 0.89, p 
0.001; game server:  2(1,19)  8.41, OR  0.94; 95% CI, 0.90 – 0.97,
p  0.004). Only for the trustworthy opponent was there a
round  treatment interaction ( 2(1,19)  16.79, OR  1.08; 95%
CI, 1.043–1.13, p  0.001): the overall level of cooperation is main-
tained on MDMA whereas it declined with placebo (Fig. 3E).
Sustained maintenance of overall cooperation with a trust-
worthy player on MDMA compared with placebo could be due to
three scenarios. First, MDMA may reduce the psychological im-
pact of an opponent’s compete decision. Second, MDMA may
cause a greater recovery of cooperation following a compete de-
cision. Third, both of these could be true. We tested these statis-
tically by defining an “impact” and “recovery” phase for each
compete decision by a trustworthy opponent. The “impact” re-
fers to the change in cooperation in the trial immediately follow-
ing the opponents’ compete decisions. The “recovery” refers to
the change in cooperation over the next four decisions (i.e., to the
next compete decision). Separate generalized estimating equa-
tion models were conducted for each of these stages.
There was a main effect of impact, such that there was a re-
duced probability that participants cooperated following a trust-
worthy opponent’s compete decision ( 2(1,19)  10.44, OR 
0.40; 95% CI, 0.23– 0.70, p  0.001). However, there was no
impact  treatment interaction ( 2(1,19)  0.21, p  0.647). There
was a main effect of recovery ( 2(1,19)  3.87, OR  1.19; 95% CI,
1.00 –1.43, p  0.049), as well as a recovery  treatment interac-
tion ( 2(1,19)  4.51, OR  1.27; 95% CI, 1.02–1.59, p  0.034):
when playing a trustworthy opponent, there was an increase in
probability of a cooperate decision during the recovery phase,
and this was greater during the MDMA session than placebo
session. For the untrustworthy opponents, there was a main effect
of both impact (in this case, of a cooperative decision) and recov-
ery (respectively:  2(1,19)  8.45, OR  1.89; 95% CI, 1.23–2.91,
p  0.004;  2(1,19)  22.85, OR  0.684; 95% CI, 0.59 – 0.80, p 
0.001). Neither analysis showed an interaction (p values 0.54),
suggesting that MDMA did not differentially affect participants’
reactions to incongruous cooperative decisions.
The above exploratory analyses suggest that the effect found in
the planned analysis can be explained by MDMA enhancing the
recovery of cooperation following the negative impact of a com-
pete decision from a trustworthy opponent.
Exploratory analysis of behavior data
An exploratory analysis was performed to investigate the rela-
tionship between changes in cooperation with trustworthy oppo-
nents and the other behavioral effects of MDMA. We performed
a forward selection stepwise regression analysis with change in
PD cooperation with trustworthy opponents as the outcome
variable. Using the stepAIC R package (Venables and Ripley,
2002), we entered change in each subscale of the ASC, each out-
come measure of the MET, and change in accuracy of each emo-
tion in the Affective Bias task, as potential predictor variables.
The method uses the Akaike Information Criterion to find the
best model to explain the outcome variable. Due to the Affective
Bias task and MET not having complete datasets, this analysis was
based on N  17.
Table 4 shows that change in PD behavior can be explained by
a broad range of MDMA effects, including subjective effects,
emotion processing, and empathic processing. We performed a
leave-one-out cross-validation analysis to assess the quality of the
model output, and found a high correlation between predicted
and observed changes in PD cooperation (Pearson’s r(15)  0.84,
p  0.001). The results suggest that the changes in cooperation
can be explained by a broad range of MDMA’s other behavioral
and subjective effects.
Functional neuroimaging
Main effect of task
To assess the main task effects, we performed a one-sample t test
for each trial phase (participant decision, feedback, trust rating)
in the placebo session, collapsing across opponent types (Table 5;
Fig. 4). There were overlapping clusters across phases in the fol-
lowing regions (FWE cluster-corrected p  0.05): (1) bilateral
paracingulate gyrus, extending bilaterally into the superior fron-
tal gyrus and middle frontal gyrus; (2) bilateral supramarginal
gyrus; and (3) right inferior frontal gyrus. A cluster was activated
in the right anterior insula/frontal operculum during the decision
phase. There was an overlapping, smaller cluster in this region
during the trust rating phase.
The bilateral supramarginal clusters activated during the feed-
back phase extended into the lateral occipital lobe and precentral
gyrus. Furthermore, this phase had larger superior frontal clus-
ters than the other two phases. Finally, a cluster in the left anterior
insula/frontal operculum region was activated during the trust
rating phase, not seen in the other phases of the task.
These regions overlap with those reported by Rilling et al.
(2004), indicating that the task design is producing results in line
4
(Figure legend continued.) plotted as scatterplots with the line of best fit for each session; for
the trustworthy opponent, there is a steady decline in cooperative decisions during the placebo
session, which does not occur during the MDMA session (generalized estimating equation
round  experimental session interaction: 2(1,19)  16.79, OR  1.08; 95% CI, 1.04 –1.13,
p  0.001). The parameter estimate for a quadratic fit of trial number was not statistically
significant. Error bars indicate SE.
Table 4. Model output for the forward selection stepwise regression
Estimate SE t p
Intercept 63.08 8.35 7.55 0.001
MET Cognitive 147.47 22.88 6.45 0.001
Affective Bias Anger 1.91 0.27 7.13 0.001
ASC Anxiety 2.51 0.32 7.95 0.001
Affective Bias Sad 1.04 0.20 5.13 0.001
ASC Elemental Imagery 0.47 0.11 4.17 0.003
ASC Impaired Cognition 0.97 0.23 4.23 0.003
ASC Bliss 0.31 0.09 3.32 0.011
ASC Complex Imagery 0.73 0.28 2.58 0.034
Model statistics Adjusted R 2 F df p
0.88 15.87 8.8 0.001
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with that which would be expected. No effects were found
(threshold of FWE-corrected p  0.05) in three one-way, within-
subject ANOVAs, looking at the effect of opponent type (trust-
worthy, untrustworthy, game server) phase during each phase of
the trial (decision, feedback, trust rating).
Treatment and opponent effects
No significant clusters were found with a flexible factorial design
examining the effect of treatment and opponent type (trustwor-
thy, untrustworthy, game server) during the decision or trust-
rating phase. Two models were run, with and without the game
server. Table 6 presents the findings from both analyses, with
Figure 5 displaying the overlap map. As the results overlap and we
were primarily interested in different types of opponent behavior,
the model excluding the game server is reported hereafter. Dur-
ing the feedback phase, there was a main effect of treatment, such
that four clusters showed greater activation on MDMA compared
with placebo: (1) left central operculum, extending to the parietal
operculum; (2) right precentral gyrus, extending to the parietal
operculum and anterior insula; (3) supplementary motor
area, extending to the midcingulate cortex (MCC); and (4)
right precuneus.
To explore these effects further, we extracted the first-level
contrast estimates. Due to the large size of the clusters resulting
from the main effect of treatment contrast, we defined spherical
ROIs centered on the peak coordinate of each of these clusters
(radius  8 mm). For the two interaction effects, we extracted the
contrast estimates from the whole clusters. We performed four
post hoc paired t tests on each cluster.
The main effect of drug in the left central operculum and right
precentral/supramarginal clusters was largely driven by increased
activation on MDMA compared with placebo when receiving feed-
back from trustworthy opponents (respectively: t(19)  5.33;
Bonferroni-corrected p  0.001; t(19)  4.37; Bonferroni-
corrected p  0.001). No other comparison survived correction
for multiple comparisons in these clusters. Post hoc comparisons
from the other two clusters of the main effect of treatment contrast
showed increased activation during the MDMA session for both
trustworthy and untrustworthy opponents.
While there was no main effect of opponent type during the
feedback phase, there was a significant opponent  treatment
interaction effect in one cluster incorporating the right anterior
insula, orbital frontal cortex, and putamen (Table 6; Fig. 6A).
Table 5. fMRI activations during the different phases of the PD in the placebo condition, collapsed across opponent typesa
MNI
Region FWE cluster-corrected p Cluster size x y z z Region
Decision phase
Right superior frontal gyrus 0.001 245 4 41 36 5.49 Superior frontal gyrus
8 26 49 5.23
8 30 36 5.05 Paracingulate gyrus
Right frontal operculum 0.004 116 41 19 7 5.33 Right frontal operculum
31 22 7 4.62 Anterior insula
Right angular gyrus 0.001 221 52 52 40 5.21 Angular gyrus
49 34 46 4.93 Supramarginal gyrus
Left supramarginal gyrus 0.011 91 49 38 46 4.14 Supramarginal gyrus
49 49 49 4.09
52 45 43 4.04
Feedback phase
Right supramarginal gyrus 0.001 717 52 45 43 5.72 Supramarginal gyrus
49 45 53 5.45
26 64 46 5.27 Lateral occipital cortex
Left lateral occipital cortex 0.001 1228 19 64 53 5.59 Lateral occipital cortex
34 45 43 5.58 Superior parietal lobule
11 101 3 5.30 Occipital pole
Right inferior frontal gyrus 0.014 96 52 11 20 4.78 Inferior frontal gyrus
Left precentral gyrus 0.004 132 52 8 33 4.33 Precentral gyrus
52 22 30 4.10 Middle frontal gyrus
Trust rating phase
Right superior frontal gyrus 0.001 511 15 22 59 5.71 Superior frontal gyrus
8 26 40 5.45 Paracingulate gyrus
11 38 33 4.37 Superior frontal gyrus
Right angular gyrus 0.001 365 52 49 46 5.52 Angular gyrus
56 56 40 5.33
52 34 46 5.27 Supramarginal gyrus
Left supramarginal gyrus 0.001 412 49 38 46 5.00 Supramarginal gyrus
52 60 36 4.95 Lateral occipital cortex
41 52 56 4.76 Superior parietal lobule
Right lateral occipital cortex 0.009 92 15 71 53 4.91 Lateral occipital cortex
11 64 49 4.75 Precuneous cortex
Left middle frontal gyrus 0.007 96 41 26 36 4.76 Middle frontal gyrus
Left inferior frontal gyrus 0.014 82 49 15 3 4.17 Inferior frontal gyrus
30 15 7 3.52 Anterior insula
Right frontal operculum cortex 0.020 75 45 19 3 4.15 Frontal operculum cortex
56 19 17 3.55
Left frontal pole 0.050. 75 41 45 3 4.11 Frontal pole
aRegions identified by the Harvard-Oxford probabilistic atlas (Desikan et al., 2006).
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During the trust rating phase, there was no main effect of treat-
ment, nor opponent type, but there was a treatment  opponent
interaction in a single cluster in bilateral dorsal caudate (Table 6;
Fig. 6B).
We extracted the first-level contrast estimates from the clus-
ters showing interaction effects. Figure 6 shows that both the
feedback phase and trust rating phase interaction effects were
driven by changes in activation for both opponents on MDMA
compared with placebo, in opposite directions: an increase in
activation for trustworthy opponents, and a decrease in activa-
tion for untrustworthy opponents.
Finally, we entered the residuals of the first-level model into a
second-level paired t test contrasting MDMA and placebo condi-
tions to test for differences in task-unrelated variations in brain
activity. This analysis returned no significant differences between
treatment conditions.
Exploratory analysis examining the relationship between changes
in neural activity and serotonin receptor densities
Given MDMA’s potent serotonergic activity (de la Torre et al.,
2004), we performed an exploratory analysis to investigate the
relationship between the neuroimaging results detailed above
and the receptor densities of the three serotonin receptors for
which MDMA has high affinity (1A, 2A, transporter). We calcu-
lated the mean receptor density of each receptor in each of the 85
regions of the Deskin-Killiany ROI atlas (Desikan et al., 2006),
using high-resolution receptor density maps from Beliveau et al.
(2017). We performed correlation analyses with the second-level
contrast maps from the analyses showing significant effects of
MDMA: the main effect of treatment during feedback, the treat-
ment  opponent type interaction during feedback, and the
treatment  opponent type interaction during the trust rating
phase. We corrected for multiple comparisons at the level of each
receptor.
We found a significant correlation between contrast estimates
and 2A receptor density for the main effect of treatment contrast
(r  0.28; Bonferroni-corrected p  0.027). For the interaction
effect during feedback, we found a significant correlation be-
tween contrast estimates and 1A receptor density (r  0.28;
Bonferroni-corrected p  0.030) and 2A receptor density (r 
0.27; Bonferroni-corrected p  0.039). For the interaction effect
in the trust rating phase, we found a significant interaction be-
tween contrast estimates and 1A receptor density (r  0.33;
Bonferroni-corrected p  0.006).
Discussion
The present findings provide evidence for context-specific mod-
ulation of cooperative behavior by MDMA. The effect of MDMA
during an iterated PD was to increase cooperation with trustwor-
thy opponents but not untrustworthy or nonsocial control oppo-
nents. This was accompanied by increased cortical activation
when receiving feedback of the trustworthy players’ decisions
during the MDMA session, in brain regions previously associated
with social interactions.
Counter to our hypothesis, mean trust ratings did not change
with MDMA administration. This suggests that participants’
changes in cooperative behavior were not due to an altered con-
ceptualization of trustworthiness per se. Rather, there was a
greater recovery of cooperation following the initial negative im-
pact of compete decisions by the trustworthy opponents. In con-
trast, when the other player consistently displayed uncooperative
behavior, participants reacted similarly on MDMA and placebo,
by increasingly protecting themselves from betrayal over the
course of the game. An exploratory analysis showed that changes
Figure 4. Main effects of each phase of the task in the placebo session. FWE cluster-corrected p  0.05.
Gabay et al. • MDMA Prisoner’s Dilemma J. Neurosci., January 9, 2019 • 39(2):307–320 • 315
in PD cooperation were associated with changes in a range of
variables related to the overall MDMA effect.
The context-specific nature of MDMA-induced changes in
behavior was reflected in the fMRI data, where we found several
interactions at the different phases of the social interaction. First,
we observed an interaction between treatment and opponent
type in a cluster incorporating the right insula, orbital frontal
cortex, and putamen. Exploring the signal changes driving this
interaction showed that, when receiving feedback on MDMA
compared with placebo, these areas had higher activation during
the interaction with trustworthy opponents, but lower activa-
tion when interacting with untrustworthy opponents. This fits
well with the proposed role of anterior insula in integrating
uncertainty, appraisal, and personal preferences proposed by
Singer et al. (2009). In turn, it has been suggested that the role
of anterior insula in the appraisal of outcomes may be linked
to its tracking of expected and experienced risk in the context
of reward processing (Sescousse et al., 2013). Below we argue
that the neural changes revealed as the main effect of MDMA
when receiving feedback may represent differential appraisal
of the opponents’ actions. The interaction effect seen in this
cluster suggests that what drives the MDMA-induced changes
in cooperation with trustworthy opponents could be the spe-
cific alteration in how these appraisals are integrated with
expected reward.
In the trust rating phase, there was also an interaction between
treatment and opponent type, such that the dorsal caudate had
increased activity on MDMA compared with placebo when inter-
acting with trustworthy opponents. Previous research in social
decision-making has interpreted caudate activation as reward
signals when receiving feedback of mutual cooperation (Rilling et
al., 2002; King-Casas et al., 2005) and when given the opportunity
to punish norm violators (de Quervain, 2004). Furthermore, in
the context of a Trust Game, where participants make decisions
on whether to trust others with a monetary investment, the dorsal
caudate has been associated with developing a model of partner
reputation through signaling an “intention to trust” (King-Casas
et al., 2005). The finding that this region is activated more on
MDMA when considering trust in trustworthy opponents, but
not with untrustworthy opponents, could represent greater po-
tential subjective reward from this evaluation, leading to stronger
reputation building and greater future cooperation.
During the feedback phase, there was a main effect of treat-
ment with MDMA increasing activity in four clusters. One of
these clusters incorporated a large amount of the left superior
temporal cortex and posterior insula/central operculum. Both
areas have previously been implicated in the processing of social
interactions. The superior temporal cortex is frequently impli-
cated in theory of mind, mentalizing and attribution of intent to
others (Rilling et al., 2004; Kestemont et al., 2015). The posterior
Table 6. fMRI activations for the PD, treatment contrastsa
MNI
Region FWE cluster-corrected p Cluster size x y z z Region
Feedback phase with the trustworthy opponent, flexible factorial including all opponent types
Main effect of treatment (MDMA  Placebo)
Precentral gyrus 0.001 875 56 4 10 4.91 Precentral gyrus
60 22 23 4.36 Supramarginal gyrus
41 8 33 4.36 Precentral gyrus
Supplementary motor area 0.001 1008 4 8 49 4.77 Supplementary motor area
4 8 49 4.73 Supplementary motor area
22 15 59 4.42 Precentral gyrus
Middle temporal gyrus 0.001 275 49 60 0 4.68 Middle temporal gyrus
52 71 10 4.18 Lateral occipital cortex
38 60 17 3.79 Lateral occipital cortex
Central opercular cortex 0.001 369 49 19 17 4.64 Central opercular cortex
41 34 20 4.17 Parietal operculum
64 34 13 3.84 Superior temporal gyrus, posterior
Feedback phase with the trustworthy opponent, flexible factorial excluding game server
Main effect of treatment (MDMA  Placebo)
Central operculum cortex 0.001 469 45 19 14 4.92 Central operculum cortex
41 38 20 4.63 Parietal operculum
45 15 3 4.01 Heschl’s gyrus
Precentral gyrus 0.001 957 60 8 10 4.83 Precentral gyrus
45 26 17 4.62 Parietal operculum
30 4 10 4.49 Anterior insula
Supplementary motor area 0.001 631 0 8 59 4.69 Supplementary motor area
8 4 43 4.56 Midcingulate
38 19 43 4.39 Postcentral gyrus
0.006 159 15 52 49 4.64 Precuneus
15 30 43 3.95 Precentral gyrus
Treatment  opponent interaction
Anterior insula 0.001 293 34 15 10 4.65 Anterior insula
34 26 10 4.53 Orbital frontal cortex
19 8 7 4.13 Putamen
Trust rating phase with the trustworthy opponent, flexible factorial excluding game server
Treatment  opponent interaction
Dorsal caudate 0.023 136 8 8 13 4.57 Dorsal caudate
15 15 13 4.04 Dorsal caudate
8 4 13 4.36 Dorsal caudate
aRegions identified by the Harvard-Oxford probabilistic atlas (Desikan et al., 2006).
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insula/central operculum has been implicated when reappraising
the intentionality of unfair offers in the Ultimatum Game, a task
where people have the opportunity punish violators of social
norms (Güth et al., 1982; Güroğlu et al., 2011; Grecucci et al.,
2013).
Neuroimaging studies have used computational modeling to
investigate how these processes relate to interactive contexts,
such as the PD (Hampton et al., 2008; Haruno and Kawato, 2009;
Bault et al., 2015). These models, while not applied directly to the
PD, provide candidate processes, which may be modulated by
MDMA. The concept of social tie, introduced by van Dijk and
van Winden (1997), represents the history of other players’ be-
havior. The greater the social tie, the greater the interacting part-
ner’s outcome affects one’s own utility. Bault et al. (2015) found
that the brain regions encoding particular parameters of this
model showed a remarkable overlap with the superior temporal
and posterior insula changes seen during feedback on MDMA in
the present study. Reappraisal of the other players’ behavior and
alterations in social tie may be one mechanism underlying the
MDMA effects seen in present study.
In a task similar to the PD, Hampton et al. (2008) investigated a
model of how one’s own strategy influences that of other players in a
task similar to the PD. They found that posterior temporal cortex
represented differences between the expected and actual influence of
one’s own behavior. Furthermore, they reported that a region over-
lapping the MCC cluster in the current analysis encoded the ex-
pected reward from the other player’s decision. The MCC cluster
here spans anterior MCC and posterior regions. Vogt (2016) argues
that anterior MCC, with high expression of DA D1 receptors,
plays a role in value-based action selection. Furthermore, this
region plays a key role in feedback-mediated decision-making.
King-Cases et al. (2005) showed MCC activity correlated with
participants’ “intention to trust” during a trust game. To-
gether, we can infer that the MCC change in the current anal-
ysis may represent alterations to the incorporation of feedback
in planning of the next decision, and its associated action.
Pharmacological mechanisms underlying the effect of MDMA
MDMA increases the synaptic availability of serotonin, DA, and
NA (de la Torre et al., 2004). The magnitude of the 5-HT effect is
Figure 5. Significant clusters from the main effect of treatment contrast, with and without including the game server in the model. FWE cluster-corrected p  0.05.
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far larger than those of DA and NA (Carhart-Harris and Nutt,
2017), and MDMA increases oxytocin levels. While we cannot
parse the effects of MDMA across these mechanisms within this
study, it would be prudent to consider the possibility that selec-
tive MDMA-induced effects, particularly via changes in NA or
DA, may be responsible for the changes reported here.
It is not possible to draw firm conclusions as to the precise
mechanisms of any 5-HT effect underlying the results reported
here. However, we conducted an exploratory analysis using high-
resolution atlases of serotonin receptor densities (Beliveau et al.,
2017), which show significant relationships between the signal
change in our neuroimaging data for the main effects of MDMA
during feedback and 5-HT2A receptor densities (r  0.28) and
the interaction effects of MDMA and opponent during feedback
and the 5-HT2A (r  0.27) and 5-HT1A (r  0.28) densities.
This is preliminary evidence that the results reported here are
likely driven by MDMA’s 5-HT activity. Equivalent density maps
would be required for DA and NA receptors to better establish
this relationship.
As has been found in previous studies (Hysek et al., 2014;
Kirkpatrick et al., 2014), MDMA administration caused a large
increase in plasma oxytocin levels. This is another potential me-
diator of the findings presented in this manuscript, particularly
when considering its impact on ingroup and outgroup relations
(De Dreu and Kret, 2016; Daughters et al., 2017). While group
membership was not manipulated in the current study, it re-
mains an interesting avenue for future research.
Limitations and implications
A limitation of the current study is the use of an inactive placebo.
Given the clear subjective effects of MDMA, participants became
aware that they had been given the active compound. This is a
recognized challenge among researchers investigating com-
pounds with potent subjective effects, such as psychedelic and
dissociative drugs.
The current study recruited only male participants. Psycho-
pharmacological studies are particularly sensitive to differences
in hormonal levels across participants. As such, single-sex studies
have more power to detect a given effect. It should be noted,
however, that gender differences have been reported in the sub-
jective effects of MDMA (Allott and Redman, 2007). As such, it is
possible that the effects reported here may not be generalizable
across genders.
Any within-participant design does hold the potential for task
learning effects as well as order effects. However, the counterbal-
anced, crossover design of this study will have minimized these
potential limitations, and our analysis of visit and order effects
did not yield significant results.
Without blocking the 5-HT2A and other candidate target re-
ceptors, it is not possible to causally attribute the effects of
MDMA to specific receptor subtypes. Alternatively, to establish
whether MDMA’s dopaminergic modulation was responsible for
the results seen here, one could include a pretreatment with a DA
antagonist, such as haloperidol.
The behavioral changes seen in the PD could be interpreted as
being a result of MDMA altering how participants process re-
ward. However, given the context-specific nature of the changes,
with changes in behavior limited to trustworthy opponents, we
do not believe this to be the case. Furthermore, Gabay et al.
(2018) reported results of a reward sensitivity task in these same
participants, showing no changes with MDMA administration.
In conclusion, the work presented here provides evidence that
MDMA alters cooperative behavior in a context-specific manner.
As well as behavioral changes in the PD, we show alterations in
Figure 6. Interaction effects for the (A) feedback and (B) trust rating phases. FWE cluster-corrected p  0.05. Boxplots represent cluster-wise, extracted first-level contrast estimates with post
hoc pairwise comparisons. * Indicates statistical significance at Bonferroni-corrected p  0.05.
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social brain regions when receiving feedback of interacting part-
ner’s decisions under MDMA (compared with placebo), when
interacting with a generally trustworthy opponent. Our work
provides testable hypotheses of the mechanisms underlying this
change in behavior: that MDMA causes a change in social tie and
appraisal of others’ actions, leading to greater recovery of coop-
eration with trustworthy partners following a breach in trust.
Crucially, there is no global change in behavior due to MDMA
effects being highly specific to trustworthy interactions as it does
not alter behavior when playing the game with untrustworthy
opponents. With MDMA showing strong potential as an adjunct
to psychotherapy in the treatment of post-traumatic stress disor-
der (Mithoefer et al., 2011), these results represent an important
and timely step in teasing apart its well-reported social and emo-
tional effects.
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